• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Healthcare

Allergan Could Pay $1 Billion for Chase Pharma

'Milestone payments' could boost deal's $125 million announced price.
By REAL MONEY
Nov 25, 2016 | 02:00 PM EST
Stocks quotes in this article: AGN, LLY, TEVA

(A longer version of this article ran at 10:30 a.m. ET on our sister site TheDeal.com, which covers the M&A industry in depth. To get great M&A coverage like this even earlier in the trading day, click here.)

By Sarah Pringle

The $125 million purchase price on a deal that Allergan (AGN) announced Monday to acquire privately held Chase Pharmaceutical Corp. could ultimately expand eight-fold to $1 billion, TheDeal has learned.

Allergan didn't disclose the value of additional potential regulatory- and sales-related milestone payments for Chase's lead candidate drug CPC-201, but Chase CEO Doug Ingram told The Deal those payments could add up to an additional $875 million.

That's good news for Chase given that Ingram said the company was only worth about $15 million a year ago.

Chase is a clinical-stage drug developer, and CPC-201 is a potential Alzheimer's disease drug. Allergan's bet on the firm comes at a time when pharmaceutical giants are struggling to find treatments for Alzheimer's disease, which affects more than 5 million people in America alone.

Just this week, Eli Lilly & Co.  (LLY) saw its shares plunge on news that its promising drug solanezumab for Alzheimer's patients with mild dementia failed to meet a late-stage clinical trial's primary endpoint.

Ingram told TheDeal that amid a "continued graveyard of failed development programs" for Alzheimer's drugs, no player looked more capable than Allergan in bringing Chase's in-development therapy to the finish line. He said that's largely why Chase opted not to run a formal auction process for the company.

For Irish-based Allergan, the deal is consistent with its "stepping stone" M&A strategy. The company has picked up several smallish early stage assets like Chase since closing the sale of its generic-drug business to Teva Pharmaceutical (TEVA) in August. Following a lengthy regulatory review process, Allergan ultimately received $33.4 billion in cash and $5.4 billion in Teva stock for that deal.

Jim Cramer and TheStreet's Chief Investment Strategist Jack Mohr bought more Allergan shares on Monday for the Action Alerts PLUS charitable portfolio. Click here for a free 14-day membership to the AAP investment club and read why, as well as to get access other exclusive content like special monthly conference calls with Cramer and Mohr.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Employees of TheStreet are restricted from trading individual securities. Action Alerts PLUS, which Cramer and Mohr co-manages as a charitable trust, is long AGN.

TAGS: Investing | U.S. Equity | Healthcare | Markets | Mergers and Acquisitions | Stocks

More from Healthcare

2 Biotech Stocks to Own as M&A Potentially Gathers Steam

Bret Jensen
May 11, 2022 11:35 AM EDT

I like these names as stand-alone entities but they should also attract interest from larger players.

China Faces 'Tsunami' of Covid Infection That Could Swamp the System

Alex Frew McMillan
May 11, 2022 9:00 AM EDT

A new study suggests 1.55 million people could die if China abandons zero-Covid, with the intensive-care system needing 15.6 times existing capacity.

I'm Giving Dynavax Another Shot -- a Booster Shot

Bret Jensen
May 8, 2022 7:31 AM EDT

Despite an earnings miss, DVAX show promise in several vaccine fronts and I'm doubling down on the name.

In This Environment, I'd Be More Risk Averse With Intuitive Surgical

Stephen Guilfoyle
Apr 25, 2022 10:50 AM EDT

The firm has been hurt and continues to be hurt by the effects of the pandemic.

CVS Stock Needs to Refill Its Prescription

Bruce Kamich
Mar 29, 2022 12:01 PM EDT

Charts are looking 'toppy' right now.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 02:24 PM EDT PAUL PRICE

    An Interesting Chart

    I'm betting heavily that stocks will be way up aga...
  • 10:10 AM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    "Market Timing for Dummies"
  • 01:44 PM EDT STEPHEN GUILFOYLE

    Stocks Under $10 Portfolio

    We're making a series of trades here.
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2022 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login